Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Upstream Processing01:27

Upstream Processing

77
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
77
Overview Of Cell Separation And Isolation01:20

Overview Of Cell Separation And Isolation

8.3K
Cell separation was first achieved in 1964 by S. H. Seal, who separated large tumor cells from the smaller blood cells using filtration. Two years later, Pohl and Hawk performed experiments on how cells respond differently to a nonuniform electric field based on the cell type. Such observations were the inception of cell separation methods, which allow isolating a single cell type from a heterogeneous sample.
8.3K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular identification of Kudoa thyrsites parasite isolated from Atlantic mackerel (Scomber scombrus) landed in Ireland.

Parasitology research·2026
Same author

Sickle cell disease 115 years later: improving health outcomes through policy, research, and collaboration, to achieve health equity.

Frontiers in health services·2026
Same author

Geographic and Temporal Differences in Sickle Cell Disease Hospitalizations in New York State.

JAMA network open·2026
Same author

Newborn enrolment, engagement, and immunisation in primary care: a qualitative study of healthcare providers' perspectives.

Journal of primary health care·2026
Same author

Revisiting FLAIR vascular hyperintensity: from flow disturbance to vessel wall disease.

European radiology·2026
Same author

Toward standardized iPSC testing: Insights from a multi-year international Quality Assessment Round.

Stem cell reports·2026

Related Experiment Video

Updated: Apr 4, 2026

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

2.8K

Concise Review: Process Development Considerations for Cell Therapy.

Andrew Campbell1, Thomas Brieva2, Lior Raviv2

  • 1International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada; Thermo Fisher Scientific, Inc., Grand Island, New York, USA; Celgene Cellular Therapeutics, Warren, New Jersey, USA; Pluristem Therapeutics Inc., Haifa, Israel; Rooster Bio Inc., Frederick, Maryland, USA; Novartis Pharmaceuticals, Morris Plains, New Jersey, USA; Pall Life Sciences (division of Pall Corp), Port Washington, New York, USA; Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore, Singapore andrew.campbell@thermofisher.com.

Stem Cells Translational Medicine
|August 29, 2015
PubMed
Summary

Developing robust cell therapy production methods is crucial for clinical success. This review outlines key process development strategies to ensure consistent, safe, and effective cell products from research to commercialization.

Keywords:
Cellular therapyMesenchymal stem cellsPluripotent stem cellsProcess developmentT cell

More Related Videos

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.9K
Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

9.9K

Related Experiment Videos

Last Updated: Apr 4, 2026

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

2.8K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.9K
Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

9.9K

Area of Science:

  • Biotechnology and Regenerative Medicine
  • Cellular Therapy Manufacturing

Background:

  • Advancing cell therapies requires robust and well-characterized production methods.
  • Ensuring product consistency, safety, and efficacy is paramount for regulatory approval and clinical success.

Purpose of the Study:

  • To introduce process development challenges in cell therapy manufacturing.
  • To describe tools and strategies for addressing production issues and optimizing processes.
  • To guide the efficient transition of cell therapies from research to commercialization.

Main Methods:

  • Review of current process development strategies for cell therapies.
  • Identification of key considerations for manufacturing optimization.
  • Discussion of tools for addressing production challenges.

Main Results:

  • Process development strategies can enhance efficiency while maintaining or improving safety and quality.
  • Early identification of manufacturing concerns increases the probability of therapeutic success.
  • A structured approach using a target product profile aids in defining critical process parameters.

Conclusions:

  • This work provides a resource for transitioning cell therapies from research to clinical and commercial stages.
  • Following outlined steps can lead to successful clinical and commercial outcomes for cell-based therapies.